Good day, and thank you for standing by. Welcome to the Nyxoah fourth quarter and full year 2025 earnings conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, we'll open up for questions. To ask a question during the session, you will need to press star one one on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star one one again. Please be advised that today's call is being recorded. I would now like to hand it over to our first speaker today, Pearson Dennis, Investor Relations Associate. Please go ahead. Thank you. Good afternoon, everyone. I welcome you to our fourth quarter and full year 2025 earnings call. Participating from the company today will be Olivier Taelman, Chief Executive Officer, and John Landry, Chief Financial Officer. During the call, we will discuss our operating activities and review our fourth quarter 2025 financial results released after U.S. market closing today. After which, we will host a question-and-answer session. The press release can be found on the investor relations section of our website. This call is being recorded and will be archived in the events section on the Investor Relations tab of our website. Before we begin, I'd like to remind you that any statements that relate to expectations or predictions of future events, market trends, results, or performance are forward-looking statements. All forward-looking statements are based upon our current estimates and various assumptions. These forward-looking statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated or implied by these forward-looking statements. All forward-looking statements are based upon current available information, and the company assumes no obligation to update these statements. Accordingly, you should not place undue reliance on these forward-looking statements. For a list and description of the risks and uncertainties associated with our business, please refer to the Risk Factors section of our Form 20-F, which will be filed with the Securities and Exchange Commission. With that, I will now turn the call over to Olivier. Thank you, Pearson. Good day, everyone, and thank you for joining us for our fourth quarter and full year 2025 earnings call. Let me start by our 2025 key milestones and highlights. 2025 was a transformative year for Nyxoah. We achieved several defining milestones during the year. In early 2025, in anticipation of FDA approval, we hired and trained our U.S. commercial team, including our first 25 sales reps. We developed our strategic launch plan, worked on securing market access, and mapped out target accounts focused on the top 400 highest volume hypoglossal nerve stimulation accounts around the U.S. On August 8th we received U.S. FDA approval for Genio, followed by actively launching our product. We secured reimbursement for Genio across both Medicare and commercial payers, resulting already in first implants and revenue as early as September 2025. We successfully executed on our focused launch in the United States. We trained 145 surgeons in 125 high-volume hypoglossal nerve stimulation accounts, of which 57 already received positive Value Analysis Committee approval, resulting in $4.5 million of revenue generated in Q4. This translates into $720,000 in annualized sales rep productivity during the first full quarter of launch. From a clinical data perspective, the DREAM pivotal study was published in the Journal of Clinical Sleep Medicine. These data demonstrated Genio's clinical efficacy in both supine and non-supine positions, as reflected in our labeling and differentiating us from competition. Internationally, we continued driving growth in selected markets, including Germany, United Kingdom and the Middle East. We closed 2025 with a global gross revenue of EUR 11 million, driven by strong Q4 U.S. launch momentum. Now let me dig in deeper, starting with our commercial update. The fourth quarter marked our first full quarter of U.S. commercialization following FDA approval, and we are excited with the first launch results. Let me share with you the key leading indicators that we are tracking, too. As of December 31, 2025, with our 25 sales reps, we focused on 125 out of the 400 top HGNS accounts in the U.S. From these accounts, 145 surgeons were trained. We completed 120 Value Analysis Committee submissions and received 57 approvals already, with no VAC rejections to date. U.S. reimbursement has been consistent for Medicare and many large commercial payers to date. For the past months, I've had the chance to meet multiple surgeons and fleet customers across the U.S., hearing consistent positive feedback on Genio's unique approach and the optionality we now offer to patients and physicians. Surgeons are attracted by the bilateral stimulation, the single incision procedure, and the consistent therapy efficacy across all sleeping positions, which makes Genio unique on the market. In their interactions with patients, they highlight the patient-centric design, including the battery-free implantable, full body MRI compatibility, and no need for re-surgery due to battery depletion or software upgrades. In addition, sleep physicians note that the first wave of activated patients in the U.S. are providing strong positive feedback on therapy outcomes. From a reimbursement perspective, ahead of FDA approval, we worked to align Genio coverage with the broad framework of hypoglossal nerve stimulation therapies across both commercial payers and Medicare. I'm pleased to report that Genio has been consistently reimbursed by both commercial payers, which represents approximately 90% of our business, and Medicare, which represents the remaining 10% of the Genio business during Q4. Recently, there has been a lot of discussion and communication regarding HGNS reimbursement overall. As is typical for a relatively new product category, in combination with an expanding landscape where Genio enters the market, procedural coding practices continue to mature. In February 2026, CMS established new interim C-codes for HGNS that facilities will use when billing for traditional Medicare patients, including specific codes C8011, C8012, and C8013, which apply to external power devices, including our Genio system. Last Friday, CMS indicated that the new C-code 8011 used for a Genio implant would be reimbursed in the hospital outpatient department at $31,526, in line with 2026 coverage for CPT code 64582. This also means that there is no reimbursement difference between the Genio system and competition. Staying with Medicare, the introduction of C-codes does not change how surgeons bill their physician fee for Medicare procedures. Surgeons are responsible for selecting the appropriate CPT code and potential modifier use. Given recent CMS guidance, we expect surgeons will elect to use CPT 64582 for their physician fee. Let us turn now to commercial payers, which represent approximately 90% of our business. Claims continue to be processed under CPT code 64582 or 64568, depending on payer policy, contractual terms, documentation, and individual case review. To date, we have seen strong prior authorization outcomes across cases submitted to commercial payers, including many of the largest in the United States. In conclusion, we view the current reimbursement environment as a normal maturation of an established therapy. With the recent clarity on the facility fee of $31,526 for the Genio C-code, we are confident this will not have any negative impact on further Genio adoption and going forward. We remain actively engaged with specialty societies and coding authorities to support long-term dedicated HGNS CPT codes. From an international update perspective, while the U.S. is the primary growth driver, international markets continue to provide a consistent revenue contribution. Our goal is to ensure each of our international markets are profitable, with Germany being the first that has reached this goal. In summary, entering the U.S. market in 2025, which is the largest HGNS market in the world, completes our transition into a commercial organization. The momentum we see in the U.S. launch reinforces our confidence in the opportunity ahead. With that, I will now turn the call over to John for a detailed overview of our financial results. Thank you, Olivier. Starting with the fourth quarter of 2025, gross revenue was EUR 6.3 million before 700,000 of revenue deferrals, mainly due to disposable patches, which are delivered over time, resulting in net revenue of EUR 5.6 million compared to EUR 1.3 million in the fourth quarter of 2024. This growth was driven by our U.S. commercial launch, which resulted in approximately EUR 3.5 million of net revenue in the fourth quarter of 2025. Gross margin was 64% in the fourth quarter. Total operating loss for the fourth quarter of 2025 was EUR 18.6 million compared to EUR 18.3 million in the fourth quarter of 2024. Notably, operating loss remained relatively stable year-over-year despite significant commercial investments made to support our U.S. commercial launch. Now let's turn to the full year 2025 results. Gross revenue was EUR 11 million before EUR 1 million of revenue deferrals, mainly due to disposable patches, resulting in net revenue of EUR 10 million, compared to EUR 4.5 million in 2024 or 122% year-over-year growth. Gross margin for the full year of 2025 was 63%. Total operating loss for the full year of 2025 was EUR 83.5 million, compared to EUR 58.8 million in 2024. The increase in total operating loss reflects the acceleration of U.S. commercialization activities in preparation for commercial launch. Our cash position as of December 31, 2025, which includes cash equivalents, and financial assets, totaled EUR 48 million. Now, as we turn to revenue guidance, we expect U.S. net revenue for both the first and second quarters of 2026 to grow 25% sequentially. This sequential growth in the U.S. reflects continued surgeon training, additional Value Analysis Committee approvals, and growing surgeon adoption. International revenue is expected to follow typical seasonal patterns. With that, I'll now turn the call back to Olivier for closing remarks. Thank you, John. For 2026, our priority is clear. Continue executing on our U.S. commercial launch. To that end, we increased already our sales force by 15 sales reps and three sales directors in the first quarter of 2026, bringing us to a total of 40 sales reps covering 200 of the top 400 hypoglossal nerve stimulation accounts. During 2026, from a clinical perspective, we are looking forward to see our 12-month ACCESS study data on complete concentric collapse and subsequent PMA supplement submission, potentially leading to a U.S. label expansion in early 2027. As a fast-growing company, we are expanding our internal manufacturing footprint to further strengthen our competitive position and improve our gross margins. We expect our 2026 execution to translate into a very strong financial profile as we gain market share in the U.S. Thank you for listening and your continued interest and support for Nyxoah. With that, I would now like to open the lines for questions and answers. Thank you. As a reminder, to ask a question, you will need to press star one one on your telephone and wait for your name to be announced. To withdraw your question, please press star one one again. Please stand by while we compile the Q&A roster. One moment for our first question. Our first question will come from the line of Adam Maeder from Piper Sandler. Your line is open. Hi, good afternoon, and thank you for taking the questions and congrats on the progress. Two questions from me. The first one is just on, you know, some of the leading indicators or metrics that you shared, Olivier. If I heard correctly, you have 120 VAC submissions that were made, I think, as of December 31st last year, and I think 57 accounts activated. Can you just kinda help bridge us, you know, for the remaining 60 or 63, you know, VAC processes and kinda where those stand? When should we expect more accounts to go active? Just talk about the funnel for new accounts as we move, you know, towards that 400 hypoglossal nerve stimulation account target? Then I had a follow-up. Thanks. Thank you, Adam. To your point, we have submitted 120 VAC submissions. Already 57 are approved. The other ones, they will be approved, and we already saw the first ones being approved in Q1. As you know, not every hospital has the same timelines when it comes to VAC approvals, but we were extremely pleased to see already the first 57 during Q4. You can expect the remaining to start being approved during Q1. That is already, I think, answering the first part of your question. The second one is regarding to the sales force and how many accounts we are covering and how many new accounts we will open in going forward. As I mentioned during my call as well, we already increased our hiring of 15 additional sales reps. We went from 25- 40. With that, on average, each of those 15 will add five new accounts, so that can go up to 75 additional accounts, resulting in 200 out of the 400 high-volume accounts that we will be covering during Q1 and then also Q2. Hope this is answering your questions. Very helpful, Olivier. Thanks for all the color there. You know, for the follow-up, I guess I'm gonna ask about complete concentric collapse and the ACCESS study. If I heard correctly, I think you're targeting early approval in 2027. Maybe just help us understand when we're actually gonna see that data presented. I assume that's this year. If you could just maybe put a finer point on submission timing, and I think that's a PMA supplement, but wanted to confirm that? Thank you. Yes. Yes, it is a PMA supplement that we will be submitting. Now, coming back on timing, we have to wait for 12-month data, so by the end of June, we will have 12-month data of all patients. We will go into the analysis of the clinical data. That will take up to 30 days. By the end of July, we should really have a good view on how the data are looking like and also using this to prepare our PMA supplement submission. We are confronted with regulatory timelines that we cannot really change and influence. That's why we calculated more or less one quarter, so 90 days that we will do once we have submitted our data, and that's how we end up entering Q1 2027 to obtain the approval. When will we publish the data? I mean, this is something we have to submit. We will do this as soon as we have our data, so somewhere July. Depending on the acceptance in the journal, we will definitely publish this data and present them during one of the conferences that we will attend. Very good. Appreciate all the color. I'll jump back in queue. Thank you. Thank you, Adam. Thank you. One moment for our next question. Our next question will come from the line of Jon Block from Stifel. Your line is open. Thanks, guys. Good afternoon. John, maybe I can just start with you. I mean, obviously helpful on some of the guidance figures, but any more color you can give us around the cash burn rate, you know, either for the quarter, Q1, or even on an annual basis when we start thinking about 2026, and then I'll just ask a follow-up. Sure, John. Thanks for the question. In terms of the cash burn, we're looking at approximately EUR 20 million in cash burn here per quarter in the near term. We raised capital in fourth quarter vis-à-vis a PIPE as well as convertible debt, which provided us additional cash to get into the first quarter of 2027. With the capital we have on the balance sheet and the cash burn, which again, EUR 20 million here in the near term, which will decrease as we gain revenue traction here in the U.S., that will provide us the capital through the first quarter of 2027. Okay. Got it. Very helpful. You know, let me pivot. Olivier, maybe for you, maybe I could throw a couple questions your way. The first one is, I believe your competitor has been pretty transparent about pursuing their own code and, you know, maybe going down that road for January 1, 2028. I think the C-codes bridge you for a little while, but your thoughts on pursuing your own code, what that will entail and what that may mean. Can you give us an actual implant number, the number of implants that were done, maybe, you know, as of the end of the year or any even color that you're willing to give us into 2026? Because, you know, clearly of those 57 accounts activated, as you should be, I mean, you're selling into the shelf a little bit when we start thinking about the revenue number. Thanks, guys. Yes. Thank you, Jon. Yes, when it comes to the reimbursement coding, I'm finally pleased that we see that there is progress made, that there is clarity also now on the facility fee, and that we fully understand what the use of a C-code or an interim C-code means and how it's impacting also the business in going forward. Yes, also on the fact that we would like to evolve to our own coding, and there we are following, in fact, the same pathway forward as competition is doing as well. I do think listening carefully and interacting with AMA and also listening carefully to what is going on is that there will be dedicated coding for Genio also in place, most likely somewhere beginning 2028. In the meantime, facility fee is clear. We are now waiting for the physician's fee. Also, although physicians and experts are telling us there that they don't expect many differences to how it used to be, meaning using the previous CPT 64582 coding also to calculate the physician fee. That is one aspect. Second, on number of implants. We decided in our leading indicators not to communicate on the precise number of implants. On the other hand, I do think it is relatively easy also to get a good estimate when you know that we generated $4.5 million of revenue in the US in Q4, and you also know what the average price is for the system being $25,000. That's also, I think, an easy way forward to get your answer there. In our KPIs, we don't give and we do not provide clear implant numbers. Hope this is answering your question, Jon. Yeah. Okay. I mean, I get the math of the ASP and the revenue, and I can do that. But again, some are sitting on the shelf, right? So you guys were previously giving implants. I guess I'm trying to just get more granular on how many implants were done, not how many units were sold, of which a subset is sitting on the shelf. But I can follow up with you offline. Thank you. No. You know what, I think it's an important question and topic that you mentioned, and I do not wanna avoid this. First of all, it's clear that we have no policy in putting products on the shelf. We also clearly don't do any consignment. I just wanna point out that there is also no consignment. The way our sales force is operating in the field on visits, when we train surgeons, they come with pre-identified patients. Once they have these patients, most of the time, they are coming with three-five patients. Based on this, we make sure that we provide them with that number of implants, and we always add one, maximum two implants, depending whether it's three or five cases they have prepared, so that there is some backup in case something would go wrong. I think I hope to answer your question more clear in that sense, Jon, because I do think it's important. We are not loading shelves, we are implanting patients. Got it. Helpful. Thank you. Thank you. One moment for our next question. Our next question will come from the line of Suraj Kalia from Oppenheimer. Your line is open. Hi, Olivier. Can you hear me all right? Yes. Perfect. Perfect. Olivier, congrats on all the progress. Hey, Olivier, just wanted to follow up on a previous question so that I get my bearings right. Your competitor's key approach. I hope you can hear me. There's some background noise. Yeah, there's some police cars driving by. My apologies. Your competitor's approach has been like, to have minimum four-five units upfront sale when a new site is added on, and the larger sites, you know, our field checks tell us, you know, you can have 10, 12 implants on the shelves. Olivier, when you say a new site comes online with, let's say, three identified patients, is your approach also really about four-five unit upfront sales? Really, for that matter, that's the right way to think about it. By the same token, Olivier, I'm curious how in the high volume centers, as LivaNova also comes online, do you think this dynamic is sustainable of, you know, respective inventory of each player on the shelf? I know it was a long question. Hopefully you got the gist of it. No, I start by answering the first part. As I was saying, we treat patients, and we do not wanna load shelves. I keep insisting on this. With the example that you used, when we have three patients that are lined up for implants, we are selling four, maximum five devices, depending on what the surgeon prefers as a potential backup. That's what we are doing. We are not additionally selling more devices that are sitting there on the shelf. We are not doing this. I do think your calculation and the example was correct. Three patients lined up for implant, we sell four, maximum five, just to make sure there is some backup just in case. That is one aspect. Second thing, you touched on LivaNova, so I was also carefully reading and hearing today's announcement, and I wanna congratulate them with this, but it also means that they are not launching actively currently, but they are waiting till somewhere Q1, if my information is correct, or somewhere beginning 2027 to launch. Now, what we do expect, if you look a little bit at the technology is, that you will have a clear differentiation. There is Genio, bilateral stimulation, external wearable component, single incision, and then there will be two players with a pacemaker platform that will be more alike and most likely also more be considered when it comes by physician in making patient choices or selection with which patient will get what. I feel very confident with our Genio differentiated approach that we can continue also rolling out successfully in going forward, and that patients also will know what to choose, a single incision with bilateral stimulation versus a pacemaker. Fair enough. One follow-up, Olivier. The 57 or so sites that you all have trained, Olivier, admittedly, it is early, but what are you seeing as the key driver for Genio, you know, in these sites? Like what is the key reason that physicians are asking, "Hey, I need this also on the shelves." The reason I ask is, look, there have been, you know, a chatter about men with beards not having, not wanting Genio, so on and so forth. Just give us an idea about what you're seeing in the field to set the stage for, you know, market share approximations, at least between the two current players? Gentlemen, thank you for taking my questions. Thank you, Suraj. Maybe starting by clarifying something. We have trained more than 57 accounts in the U.S., just to be very clear about this. We have already 145 surgeons, and they represent or they are active in 120 accounts of the 125 high volume accounts that we are targeting. We have trained in 120 accounts. The 57 number is the number where we already have a full approval, where the fact is approved and where we actively were doing business during Q4. Just to clarify this one. Answering the question on why are surgeons choosing Genio, and I think you can summarize it in three major buckets. First of all, there is the optionality that we are providing by breaking the monopoly that was existing, and not all patients like or accept a pacemaker. Second, there is the Genio differentiation. A clear single incision implant technique, something that resonates extremely well with surgeons to having a single incision compared to multiple incisions. Then last, for a surgeon, also the bilateral stimulation and the related quality of airway opening with a beautiful tongue protrusion. This is something that we are hearing back constantly, also with staying efficient in complex airway obstructions. Those are the three things. I hope this is answering your question. Yes. Thank you. Thank you. Once again, star one one for questions. Star one one. Our next question will come from the line of David Rescott from Baird. Your line is open. Great. Good afternoon, guys, and thanks for the question. This is Tommy Han on for Dave. I was wondering if you guys would like to put a finer point on your assumptions and guidance around new account adds versus increasing utilization in your existing accounts relative to the Q4 exit rate? Yeah. As I was mentioning how we have a focused approach with the 24 salespeople starting immediately post FDA approval, we were able to reach 125 out of the 400 high-volume. Today, we added 15 reps, so now we are already reaching out to 200 out of the 400 accounts. Next to this is we have already trained 145 surgeons. We have surgeons lined up for training. There are even waiting lists, so we are doing trainings almost every weekend across the U.S., and we will also significantly increase the number of accounts we can do business with and we can implant patients. That can go up all the way to 200. In the meantime, of course, there is each time the VAC submission that takes place, it is depending a little bit account by account, how fast it can go. We see that it can happen sometimes in two weeks, sometimes it takes a month, sometimes even longer. What you can expect in gradually scaling up is that over time, and when I define over time, by the end of Q1, we should be covering all the way up to potentially 200 implant accounts where we are present. Great. Thank you. I was wondering if you guys wanted to provide a little bit more color around OpEx guidance and gross margin guidance for 2026 and what the drivers are behind that. Separately, maybe for procedures performed so far, can you help us understand where those patients are coming from? Is it those who are expecting to get another HGNS device or more so people who had been waiting on the sidelines? Thank you. Yes. I will take the last part of the question and the first part I will hand over to our CFO, to John. The last part, where are patients coming from? It is clear that in those high volume accounts, there are well-established referral networks, and we see patients being referred the moment that they arrive with the surgeon. Today, with Genio, there is optionality. Patients are proposed both technologies, and we see that a high number of these patients are choosing for Genio for the reasons I mentioned, from a surgeon perspective. But when it comes to patients, what is driving them is that, in fact, Genio is designed so patients can forget they even have an implant. It's a very minimally invasive surgery, and it's also designed to evolve with patients. As example, upgradeable software, an intuitive patient app, and no need for resurgery. That is where we see a lot of patients being very appealed by when they once are confronted and being proposed and explained what Genio can do. That is one aspect. In going forward, it's also clear that we are establishing strong relationships with sleep physicians and that we are also working on referring our own Genio patients. John, with that, maybe on the gross margins. Yes, thanks for the questions there, Tommy. On the model, in regards to gross margin, I would expect gross margin to increase slightly over the balance of the year, really due to increased sales volume and being able to spread the overhead over more units. You'll see a slight increase in 2026 as we move through the year. The major step function increase in gross margin that you can expect to see is probably more in early 2027 when we launch our next generation disposable patch activation chip or Genio 2.2 specifically. That will allow us to have an enhanced patient experience, plus also allow us to significantly reduce the cost of the disposable patch going forward. The next step function up, you know, into, say, the 70% range will come in 2027. In terms of OpEx, we don't provide specific OpEx numbers in terms of guidance, but let me give you some color here, if I can, to provide some direction. In terms of our R&D expense, which includes things like quality, regulatory, medical affairs, clinical, in addition to the true R&D spend, what you can expect to see there is that number to go down over the course of 2026, sequentially on a quarterly basis as some of the investments that we made in 2025 getting ready for commercialization, will start to fall off over the course of 2026. In regards to SG&A, the main driver there, Tommy, is really around U.S. sales expansion. As Olivier mentioned, we expanded by 15 sales reps in 2026 in the first quarter. You can expect our Q3, Q4 run rate to increase due to the increase of these 15 sales reps as well as their three respective sales directors. That would be the major investments we make in the SG&A sphere this year. All the other infrastructure investments, we're going to leverage those as we build those out in 2025. Hopefully that's helpful as you think about the model and that's where we're looking at for 2026. Yep, very helpful. Thanks for the color. You're welcome. Thank you. I'm not showing any further questions at this time. With that, this concludes the question and answer session. Thank you for your participation in today's conference. This does conclude the program. You may now disconnect. Everyone, have a great day.